文献速递消化道肿瘤放疗姑息放疗与转移瘤

局部进展期低位直肠癌括约肌侵犯者新辅助放化疗豁免腹股沟及髂外淋巴结照射的失败风险

Is Elective Inguinal or External Iliac Irradiation During Neoadjuvant (Chemo)radiotherapy Necessary for Locally A dvanced Lower Rectal Cancer With Anal Sphincter Invasion?
PubMed 文献 · Pract Radiat Oncol · 2021-10-17

本研究纳入214例治疗的局部进展期低位直肠癌伴肛门括约肌侵犯患者,在新辅助放化疗中豁免临床阴性腹股沟淋巴结(ILN)和髂外淋巴结(ELN)照射。中位随访53.3个月,3年ILN和ELN失败率分别为3.7%和3.3%,仅1例孤立ILN失败、无孤立ELN失败,提示豁免照射与可接受的低失败风险相关。

要点

  • 临床阴性ILN和ELN豁免照射后3年失败率分别为3.7%和3.3%。
  • 仅1例孤立ILN失败,无孤立ELN失败发生。
  • 肿瘤下缘侵犯或位于齿状线以下、高组织学分级和神经侵犯与ILN失败显著相关。

核心结论

  • 对新辅助放化疗的局部进展期低位直肠癌伴肛门括约肌侵犯患者,豁免ILN和ELN照射与可接受的低失败风险相关。

研究设计与样本

  • 回顾性纳入2010年9月至2019年5月间214例经治疗前MRI判定伴肛门括约肌侵犯、接受新辅助放化疗后手术的局部进展期低位直肠癌患者。
  • 治疗前ILN和ELN临床阴性并排除在照射范围外,分析失败率、失败模式及生存,并构建预测ILN和ELN失败风险的列线图。

主要发现

  • 中位随访53.3个月,3年ILN失败率为3.7%,ELN失败率为3.3%。
  • 仅1例发生孤立ILN失败,无患者发生孤立ELN失败。
  • 预测ILN和ELN失败风险的列线图一致性指数分别为0.842和0.880;全队列3年局部无复发生存率94.6%(95%CI 91.3%-97.9%)、无病生存率77.7%(95%CI 71.8%-83.6%)、总生存率91.9%(95%CI 87.8%-96.0%)。

关键数值与推荐

  • 3年ILN失败率3.7%,ELN失败率3.3%。
  • 列线图预测ILN和ELN失败风险的一致性指数分别为0.842和0.880。

临床怎么用

  • 对治疗前MRI评估ILN和ELN临床阴性的局部进展期低位直肠癌伴肛门括约肌侵犯患者,可考虑在新辅助放化疗中豁免ILN和ELN照射。
  • 存在肿瘤下缘侵犯或位于齿状线以下、高组织学分级、神经侵犯等风险因素者,可用列线图评估ILN和ELN失败风险以辅助靶区勾画决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the impact of excluding irradiation of inguinal lymph nodes (ILNs) and external iliac lymph nodes (ELNs) during neoadjuvant (chemo)radiotherapy in a locally advanced lower rectal cancer (LALRC) with anal sphincter invasion. METHODS AND MATERIALS: A total of 214 LALRC patients with anal sphincter invasion according to pre-treatment magnetic resonance imaging who underwent neoadjuvant (chemo)radiotherapy followed by surgery between September 2010 and May 2019 were enrolled. ILNs and ELNs were clinically negative pre-treatment and were excluded from irradiation. Failure rates and patterns of ILNs and ELNs and survival were analyzed. Nomograms for predicting ILN and ELN failure risk were also constructed. RESULTS: The median follow-up was 53.3 months. The 3-year failure rates were 3.7% for ILNs and 3.3% for ELNs. Only 1 patient developed isolated ILN failure, and no patient experienced isolated ELN failure. Multivariate analyses demonstrated that lower edge of tumors invaded or located below the dentate line (odds ratio [OR], 7.513; P = .013), high histological grade (OR, 6.892; P = .017), and perineural invasion (OR, 7.111; P = .023) were significantly related to ILN failure. Both perineural invasion (OR, 8.923; P = .011) and high histological grade (OR, 8.129; P = .011) showed a strong correlation with ELN failure. The concordance index of nomograms for predicting ILN and ELN failure risk were 0.842 and 0.880, respectively. The 3-year local recurrence free survival, disease-free survival, and overall survival were 94.6% (95% confidence interval [CI], 91.3%-97.9%), 77.7% (95% CI, 71.8%-83.6%), and 91.9% (95% CI, 87.8%-96.0%), respectively, for the whole cohort. CONCLUSIONS: Excluding ILNs and ELNs from irradiation was associated with an acceptably low failure risk for LALRC invading the anal sphincter. These findings help to refine existing guidelines for clinical target volume delineation of ILNs and ELNs during neoadjuvant (chemo)radiotherapy in rectal cancer.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Song M, Li S, Zhang Y, et al. Is Elective Inguinal or External Iliac Irradiation During Neoadjuvant (Chemo)radiotherapy Necessary for Locally A dvanced Lower Rectal Cancer With Anal Sphincter Invasion? Pract Radiat Oncol. 2021. PMID: 34670136. doi:10.1016/j.prro.2021.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。